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Expression of anti-Mullerian hormone receptor on the
appendix testis in connection with urological disorders
Korne´l Kistama´s1, Olga Ruzsnavszky1, Andrea Telek1, Lı´via Kosztka2, Ilona Kova´cs2, Beatrix Dienes1,
La´szlo´ Csernoch1 and Tama´s Jo´zsa3,4
The female internal sex organs develop from the paramesonephric (Mullerian) duct. In male embryos, the regression of the Mullerian
duct is caused by the anti-Mullerian hormone (AMH), which plays an important role in the process of testicular descent. The
physiological remnant of the Mullerian duct in males is the appendix testis (AT). In our previous study, we presented evidence for the
decreased incidence of AT in cryptorchidism with intraoperative surgery. In this report, the expression of the anti-Mullerian hormone
receptor type 2 (AMHR2), the specific receptor of AMH, on the AT was investigated in connection with different urological disorders,
such as hernia inguinalis, torsion of AT, cysta epididymis, varicocele, hydrocele testis and various forms of undescended testis. The
correlation between the age of the patients and the expression of the AMHR2 was also examined. Reverse transcriptase-polymerase
chain reaction (RT-PCR) and immunohistochemistry were used to detect the receptor’s mRNA and protein levels, respectively. We
demonstrate that AMHR2 is expressed in the ATs. Additionally, the presence of this receptor was proven at the mRNA and protein
levels. The expression pattern of the receptor correlated with neither the examined urological disorders nor the age of the patients;
therefore, the function of the AT remains obscure.
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INTRODUCTION
The female internal sex organs—oviducts, uterine horns, cervix and
the anterior vagina—develop from the paramesonephric (Mullerian)
duct. In male embryos, during embryonic development, the regres-
sion of the Mullerian duct is caused by the anti-Mullerian hormone
(AMH)/substance. According to recent theories, the abdominal part
of the testicular descent is controlled by the AMH,1 and the absence of
or genetic abnormalities in AMH or its receptors lead to the develop-
ment of persistent Mullerian duct syndrome and cryptorchidism
by preventing normal testicular descent.2,3 The vestigial remnant of
the Mullerian duct is called the appendix testis (AT; hydatid of
Morgagni) and is located at the upper pole of the testis or in the groove
between the testis and the epididymis.4 The incidence of AT is
reported as being between 76% and 92%,5,6 but this rate is decreased
in cryptorchidism,5 suggesting a possible role of AT in the complex of
testicular descent. AT is a structural unit that contains gelatinous
vascular connective tissue stroma covered by Mullerian-type epithe-
lium with subepithelial capillaries and lymphoid vessels. We do not
know if it has any physiological function; currently, the known clinical
importance of AT is that its torsion causes acute scrotum, and
tumours can develop from it.
The cremaster muscle is a striated muscle with some differences from
other skeletal muscles, such as its firing frequency and involuntary
control.7 A recent theory of testicular descent suggests the role of sym-
pathetic nerves, which innervate the gubernacular smooth and striated
muscles.8,9 In mice, AMH is not essential for gubernacular development
or testicular descent, although it is important in determining the thick-
ness of the cremaster muscle.10
There is no information on the expression of anti-Mullerian hor-
mone receptor type 2 (AMHR2) in AT, although it is possible that the
cells of AT express this receptor during embryonic development and
most likely after birth as well. Torsion of the AT is painful, and patients
with this condition show similar symptoms to those with torsion of
the testis. Therefore, removal of the AT is medically indicated when it
appears during intrascrotal operations.11 Appendices from such
operations were used in our research as well as specimens of the cre-
master muscle. The relationship between several urological diseases
and the expression of AMHR2, the specific receptor for AMH, in ATs
was investigated in this study.
MATERIALS AND METHODS
Collection of the samples
A total of 109 ATs and nine cremaster muscles were collected from
male patients undergoing surgical exploration at the Surgical Ward of
the Department of Pediatrics, Medical and Health Science Center,
University of Debrecen, Debrecen, Hungary. The study protocol was
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approved by the Human Ethics Committee of Medical and Health
Science Center, University of Debrecen. Written informed consent
was obtained from the parents or guardians before the children
entered the study. The samples used for the polymerase chain reaction
(PCR) experiments were collected from patients suffering from the
following diseases: hernia inguinalis, torsion of AT, cysta epididymis,
varicocele, ectopic testis, testis retractile, retention testis and hydro-
cele. The samples used for the immunohistochemistry experiments
were obtained from patients suffering from the following diseases:
hydrocele, retention testis, varicocele, cysta epididymis and hernia
inguinalis.
Immunohistochemistry
For immunohistochemistry, 4-mm thick, formalin-fixed sections were
used. First, the sections were rehydrated (435 min xilol and 431 min
ethanol), and to uncover the antigens, the sections were boiled in
citrate buffer (2 min, 0.1 mol l21, pH56.0). The activity of endo-
genous peroxidases was inhibited with hydrogen peroxide (10 min,
3%). Next, the nonspecific binding sites were blocked with 2.5% horse
serum (20 min, room temperature, ImmPRESS kit; Vector
Laboratories, Burlingame, CA, USA). Then, the AMHR2-specific
primary antibody (diluted in phosphate-buffered saline containing
1% bovine serum albumin, produced in mouse; AbCam,
Cambridge, UK) was used in a 1 : 300 dilution (final concentration
6.7 mg ml21). After washing the sections (phosphate-buffered saline,
335 min), they were incubated with horseradish peroxidase-conju-
gated secondary antibody (30 min, room temperature, ImmPRESS kit;
final concentration 1 mg ml21), and then the sections were washed
again (phosphate-buffered saline, 335 min). The reaction was visua-
lized by ImmPACT DAB kit (Vector Laboratories), according to the
manufacturer’s protocol. Nuclei were revealed by haematoxylin (10 s),
and sections were dehydrated (231 min ethanol, 331 min acetone
and 231 min xilol) before being covered by Shandon Consul Mount
medium (Thermo Scientific, Budapest, Hungary). Endometrium sec-
tions were used as a positive control. Negative controls were made by
omitting the primary antibody.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
analysis
For RT-PCR analysis, samples were stored in RNAlater (Ambion; Life
Technologies, Budapest, Hungary) at 270uC. Total ribonucleic acid
(RNA) was isolated from tissues using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA). Tissues were sonicated in 1 ml TRIzol (Invi-
trogen) reagent (3310 s), and then 0.2 ml chloroform was added to
the samples. Samples were mixed well and centrifuged (12 000g, 15 min,
4uC). The upper, colourless phase, which contains the RNA, was used.
It was then gently mixed with 0.5 ml isopropanol and incubated for 1 h
at 220uC and centrifuged again (12 000g, 10 min, 4uC). The sediment
was washed with 75% ethanol and dissolved in nuclease-free water.
The assay mixture (20 ml) for the reverse transcriptase reaction (Omni-
script; Qiagen, Budapest, Hungary) contained 500 ng RNA, 0.25 ml
RNase inhibitor, 0.25 ml oligo(dT), 1 ml dNTP (200 mmol ml21) and
1 ml M-MLV RT in 13 RT buffer.
Amplifications of specific complementary deoxyribonucleic acid
sequences were performed with specific primers. PCR reactions were
allowed to proceed in a final volume of 50 ml (containing 1 ml each
of forward and reverse primers, 1 ml dNTP [200 mmol l21], and 5 U
Promega GoTaq DNA polymerase in 13 reaction buffer) in a pro-
grammable thermocycler (Eppendorf Mastercycle, Netheler; Hinz
GmbH, Hamburg, Germany) with the following settings: 2 min at
95uC for initial denaturation followed by repeated cycles of denatura-
tion at 94uC for 1 min, primer annealing for 60 s at an optimized
temperature, and extension at 72uC for 1 min 30 s. After the final cycle,
further extension was allowed to proceed for another 10 min at 72uC.
PCR products were analysed using a 1.5% agarose gel. EZVision
(Amresco, Solon, OH, USA) was used as loading dye and the results
were observed in UV light. Densitometry analysis was performed using
Image J software (Wayne Rasband; National Institutes of Health,
Bethesda, MD, USA). Together with the anti-Mullerian hormone
receptor (AMHR), glyceraldehyde-3-phosphate dehydrogenase
mRNA expression was also determined and used as an internal control.
Primer design
The specific primers (Integrated DNA Technologies, Coralville, IA,
USA) were designed based on published nucleotide sequences.
Primers were designed using the NCBI (National Center for
Biotechnology Information), Primer Premier software (PREMIER
Biosoft International, Palo Alto, CA, USA) and the NCBI Primer-
BLAST program (Basic Local Alignment Search Tool). Primers were
screened for secondary structures, hairpins, dimers, homologies and
physical properties.
The sequences of the primer pairs were as follows:
Glyceraldehyde-3-phosphate dehydrogenase: forward 59-AAGGTC-
GGAGTCAACGGATTTGG-39, reverse 59-AATGAGCCCCAGCCTT-
CTCCAT-39; AMHR2: forward 59-TCGGGAAGATGGATCGTGT-39,
reverse 59-GGAAGGGTGGTGGACTGCT-39.
Statistical methods
Statistical analysis was performed using SigmaStat software (Aspire
Software International, Ashburn, VA, USA). Most of the observed data
failed to show a normal distribution (P,0.05); therefore, non-para-
metric tests (Spearman correlation coefficient) were used to assess age-
dependent correlations. The expression of AMHR2 was evaluated
using Fisher’s exact test to determine if there were nonrandom asso-
ciations between two disease types.
RESULTS
ATs and pieces of cremaster muscles were collected from patients
suffering from various urological diseases. The mRNA expression of
AMHR2 in these samples was determined using RT-PCR.
Glyceraldehyde-3-phosphate dehydrogenase was used as an internal
control. For ATs, in patients with retractile testis (n59), the mRNA of
the receptor was detected in only one sample (11%), whereas in
patients with torsion of AT (n53) and cysta epididymis (n51), most
of the samples (67% and 100%, respectively) were positive. The
mRNA of the AMHR2 was not detectable in the ATs from the patients
suffering from ectopic testis and varicocele (n52 and n51, respec-
tively). In the samples of hernia inguinalis (n514), the mRNA of the
receptor was shown in 50% of the samples, whereas in the case of
hydrocele testis (n513), only 15% of the samples were positive for
the mRNA of the receptor. In the samples with retention testis (n517),
the mRNA was present in 35% of the ATs (Figure 1a). Statistical
calculation did not show any association between the positivity under
different circumstances (P.0.05).
The protein level expression of AMHR2 was demonstrated by
immunohistochemistry. The presence of the receptor was observed
in the interstitium of the AT in immunohistochemistry sections
(Figure 2). The protein of the receptor was detectable in 25% of the
samples of patients with cysta epididymis (n512), in 67% of the
samples of hernia inguinalis (n56), in 64% of the samples of hydrocele
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testis (n525) and in 100% of the samples of retention testis (n53). In
cases of varicocele (n53), the protein of AMHR2 was shown in only
one sample (33%) (Figure 3a). No association was shown by statistical
tests (P.0.05).
The age dependence of the mRNA and protein expression of
AMHR2 in AT was also investigated by Spearman’s correlation coef-
ficient. No correlation was found between the ages of the patients and
the mRNA expression of this receptor (P.0.05) (Figure 1b). In con-
trast, the protein level expression of AMHR2 did show some age
dependence. Under the age of 12, i.e., before puberty, all of the AT
samples expressed the AMHR2 protein. However, above the age of 12,
there was no correlation between the presence of the AMHR2 and the
age of the patients (Figure 3b).
Investigations of the cremaster muscles showed that the mRNA of
AMHR2 could not be detected in patients who suffered from hernia
inguinalis (n53). In retention testis, one of the samples was positive
for AMHR2, whereas the other was negative (n52). AMHR2 was
detectable in three of the four samples of hydrocele testis (n54)
(Figure 4).
DISCUSSION
AMH is secreted by immature Sertoli cells. The serum level of AMH
stays high in males until puberty.12 Defects of the AMH and AMHR2
cause persistent Mullerian duct syndrome,2,13 where some of the
internal females sex organs can be found in a male. AMH has been
evaluated by several groups as a potential novel clinical marker for
ovarian reserve.14 Serum AMH concentrations show a progressive
decline with female ageing.14 Testicular AMH production increases
in response to follicle-stimulating hormone and is potently inhibited
by androgens. Serum AMH is undetectable in anorchid patients. In
primary or central hypogonadism affecting the whole gonad estab-
lished in fetal life or in childhood, all testicular markers are low.
Conversely, when hypogonadism only affects Leydig cells, serum
AMH is normal. In males of pubertal age with central hypogonadism,
AMH is low.15 Recent studies show that the transabdominal phase of
testicular descent is under the control of insulin-like peptide 3 and
AMH, and the studies assume a role for the cremaster muscle.16
The significantly lower presence of AT in patients with undescended
testis5 suggests that AT might play a role in the process of testicular
descent; therefore, the question arises as to whether a demonstrable
relationship can be found between AMH receptor expression in AT in
cryptorchidism compared with that of other peri-testicular disorders.
Figure 2 Visualisation of AMHR2 on paraffin-embedded 4-mm thick sections.
Brown staining (DAB) represents the AMHR2. Scale bar5200mm (a) and 100mm
(b). AMHR2, anti-Mullerian hormone receptor type 2; DAB, diaminobenzidine.
Figure 3 Detection of AMHR2 protein expression with immunohistochemistry
(n=49). On panel (a) the age dependence of the expression of AMHR2 in the AT
was shown. (b) The expression of AMHR2 in different urological disorders.
AMHR2, anti-Mullerian hormone receptor type 2; AT, appendix testis.
Figure 4 Detection of mRNA of AMHR2 with RT-PCR on cremaster muscles in
connection with different urological disorders (n59). AMHR2, anti-Mullerian
hormone receptor type 2; AT, appendix testis; RT-PCR, reverse transcriptase-
polymerase chain reaction.
Figure 1 Detection of AMHR2 mRNA with RT-PCR on ATs (n560). (a) The age
dependence of the appearance of AMHR2 mRNA in the AT. (b) The appearance
of mRNA of AMHR2 in different urological disorders. AMHR2, anti-Mullerian
hormone receptor type 2; AT, appendix testis; RT-PCR, reverse transcriptase-
polymerase chain reaction.
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Furthermore, it is likely that the cells of AT express the AMHR2;
however, there was no information about the expression of AMHR2
in AT.
For the first time, we have shown that both the mRNA and the
protein of the AMHR2 are detectable in the AT. Although the
mRNA of AMHR2 was present in several samples, the lack of
mRNA expression of the receptor did not show any relationship with
the most common urological disorders, such as the hernia inguinalis,
retention testis or hydrocele testis. Although the results from patients
with retractile testis seemed to indicate a connection between the lack
of AMHR2 and the development of this urological disorder, it is,
nevertheless, believed to be due to statistical fluctuation, because in
related pathological circumstances (retention testis and hernia ingui-
nalis), there were no similar observations.
Samnakay et al.17 found that rising levels of androgens and oestro-
gens in pubertal boys may account for enlargement and the predis-
position of the human AT to torsion because this structure contains
receptors for both. In our study, we examined the possible role of
AMH in this process and found that the mRNA of this receptor is
present in most of the samples of the torsion of AT and cysta epididy-
mis, although the number of samples was quite low. In the examined
samples obtained from patients with various urological diseases, the
mRNA and protein levels showed diverse expression patterns. This
observation strengthens the suggestion that the prevalence of AT is
incidental in postnatal life.18
There was also no correlation between the mRNA expression of
the AMHR2 and the age of the patients. We found some corres-
pondence between the protein expression of AMHR2 and the
patients’ ages—all patients younger than 12 years expressed the
AMHR2 in their AT; however, the PCR results unfortunately did
not show the same relationship. In the population over 12 years, we
could not find any correlation between the expression pattern and
age. The mRNA expression of AMHR2 in cremaster muscles also
did not show any connection with the above-mentioned urological
disorders.
The AMHR2 on AT was first detected by our research group. Our
study did not reveal any connection between the expression of
AMHR2 and undescended testis; therefore, our results did not prove
any physiological function for AT. A variety of urological disorders
were investigated to describe the function of the AMHR2 on AT.
However, because elevated expression of mRNA and protein was
found in particular diseases, the AMHR2 cannot be used as an unam-
biguous indicator of any examined urological disorder.
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